Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
Article in Expert Review of Pharmacoeconomics & Outcomes Research (July 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in Expert Review of Pharmacoeconomics & Outcomes Research (July 2024)
Article in Frontiers in Pharmacology (July 2024)
Article in Frontiers in Immunology (April 2024)